1. In Vivo
  2. >>Growth

Driving The Agenda For Next-Generation Pan-European Life Sciences Development

The Incubator As An Innovation Hub, Thoughts From BioInnovation Institute CEO Jens Nielsen

 
• By Jens Nielsen

The COVID-19 pandemic has demonstrated the need for society to address health care challenges at speed – we ignore them at our peril. Equally, it has highlighted the power that can be deployed to develop new pharmaceuticals when the life sciences sector collaborates internationally to tackle a common cause.  

Map of Europe

The importance of fostering good scientific research is at the core of innovation. Technological and therapeutic breakthroughs require input from many aspects of the life sciences ecosystem, and incubators with a far-reaching, international outlook are ideally positioned to drive development on both a micro and macro scale.

In recent years, we have seen the impact that philanthropically backed organizations such as the Gates Foundation and, closer to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

More from In Vivo

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.